- Home
- SXI vs NVCR Comparison
SXI vs NVCR Comparison
Compare SXI & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXI
- NVCR
- Stock Information
- Founded
- SXI 1955
- NVCR 2000
- Country
- SXI United States
- NVCR Switzerland
- Employees
- SXI N/A
- NVCR N/A
- Industry
- SXI Industrial Machinery/Components
- NVCR Medical/Dental Instruments
- Sector
- SXI Industrials
- NVCR Health Care
- Exchange
- SXI Nasdaq
- NVCR Nasdaq
- Market Cap
- SXI 2.3B
- NVCR 1.9B
- IPO Year
- SXI N/A
- NVCR 2015
- Fundamental
- Price
- SXI $156.46
- NVCR $16.69
- Analyst Decision
- SXI Strong Buy
- NVCR Buy
- Analyst Count
- SXI 3
- NVCR 6
- Target Price
- SXI $223.33
- NVCR $32.83
- AVG Volume (30 Days)
- SXI 102.8K
- NVCR 1.6M
- Earning Date
- SXI 07-31-2025
- NVCR 07-24-2025
- Dividend Yield
- SXI 0.82%
- NVCR N/A
- EPS Growth
- SXI N/A
- NVCR N/A
- EPS
- SXI 5.04
- NVCR N/A
- Revenue
- SXI $748,252,000.00
- NVCR $621,711,000.00
- Revenue This Year
- SXI $9.67
- NVCR $5.56
- Revenue Next Year
- SXI $12.91
- NVCR $9.19
- P/E Ratio
- SXI $31.15
- NVCR N/A
- Revenue Growth
- SXI 2.67
- NVCR 18.27
- 52 Week Low
- SXI $128.85
- NVCR $14.17
- 52 Week High
- SXI $212.66
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- SXI 54.88
- NVCR 43.44
- Support Level
- SXI $151.79
- NVCR $17.20
- Resistance Level
- SXI $158.44
- NVCR $18.02
- Average True Range (ATR)
- SXI 3.94
- NVCR 1.04
- MACD
- SXI 0.31
- NVCR -0.09
- Stochastic Oscillator
- SXI 81.43
- NVCR 15.51
About SXI Standex International Corporation
Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. It has five reportable segments; Electronics; Engraving; Scientific; Engineering Technologies and Specialty Solutions. The maximum revenue is generated from its Electronics segment which is a component and value-added services provider of both sensing and switching technologies as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging among others. Geographically, it derives key revenue from the United States and the rest from Asia Pacific, Europe, Middle East and South Africa (EMEA), and other regions.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.